Singapore markets closed

Novartis AG (NVSEF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
85.61-0.46 (-0.54%)
At close: 01:13PM EST
Full screen
Loading interactive chart…
  • Zacks

    Novartis (NVS) Q4 Earnings Top, Revenues Miss Estimates

    Novartis (NVS) reports mixed fourth-quarter results, with key brands maintaining momentum but Cosentyx sales declining and generic competition remaining a drag.

  • Motley Fool

    Novartis Ag (NVS) Q4 2022 Earnings Call Transcript

    NVS earnings call for the period ending December 31, 2022.

  • Reuters

    Novartis says operating profit to grow again ahead of Sandoz spin-off

    Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last year, as the Swiss drugmaker prepares to spin off its Sandoz generics business. Full-year core operating income was broadly flat at $16.7 billion, it said in a statement, coming in slightly below market expectations of $16.8 billion. Adjusted for overall negative currency effects, group sales in 2022 advanced 4% to $50.5 billion as gains from heart failure drug Entresto and multiple sclerosis (MS) drug Kesimpta were partly offset by competition from cheap generic copies of established MS drug Gilenya.